HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,187 | -19.2% | 214,352 | -23.7% | 0.01% | -16.7% |
| Q2 2023 | $10,129 | +36.3% | 280,822 | +44.3% | 0.01% | +100.0% |
| Q1 2023 | $7,434 | +12.0% | 194,628 | +66.8% | 0.00% | 0.0% |
| Q4 2022 | $6,638 | -99.8% | 116,654 | +4.7% | 0.00% | -40.0% |
| Q3 2022 | $4,404,000 | +174.1% | 111,386 | +205.1% | 0.01% | +400.0% |
| Q2 2022 | $1,607,000 | -45.9% | 36,511 | -51.0% | 0.00% | -50.0% |
| Q1 2022 | $2,970,000 | -82.7% | 74,448 | -82.6% | 0.00% | -33.3% |
| Q4 2021 | $17,198,000 | +214.6% | 427,754 | +218.3% | 0.00% | +50.0% |
| Q3 2021 | $5,466,000 | -6.2% | 134,401 | +4.7% | 0.00% | -33.3% |
| Q2 2021 | $5,828,000 | -41.8% | 128,338 | -46.6% | 0.00% | -40.0% |
| Q1 2021 | $10,012,000 | +31.7% | 240,143 | +34.9% | 0.01% | +25.0% |
| Q4 2020 | $7,605,000 | +23.1% | 178,072 | -24.2% | 0.00% | 0.0% |
| Q3 2020 | $6,177,000 | +3.0% | 235,037 | +5.1% | 0.00% | -20.0% |
| Q2 2020 | $5,999,000 | +110.2% | 223,724 | +41.2% | 0.01% | +150.0% |
| Q1 2020 | $2,854,000 | -19.1% | 158,485 | -20.3% | 0.00% | 0.0% |
| Q4 2019 | $3,526,000 | +91.7% | 198,900 | +67.7% | 0.00% | +100.0% |
| Q3 2019 | $1,839,000 | -15.9% | 118,578 | -6.8% | 0.00% | 0.0% |
| Q2 2019 | $2,187,000 | +28.9% | 127,288 | +20.8% | 0.00% | 0.0% |
| Q1 2019 | $1,697,000 | +130.6% | 105,346 | +109.8% | 0.00% | 0.0% |
| Q4 2018 | $736,000 | -66.0% | 50,219 | -57.9% | 0.00% | 0.0% |
| Q3 2018 | $2,166,000 | +511.9% | 119,211 | +466.7% | 0.00% | – |
| Q2 2018 | $354,000 | -93.8% | 21,036 | -92.8% | 0.00% | -100.0% |
| Q1 2018 | $5,725,000 | +321.9% | 292,225 | +336.8% | 0.01% | +400.0% |
| Q4 2017 | $1,357,000 | +96.1% | 66,903 | +68.1% | 0.00% | 0.0% |
| Q3 2017 | $692,000 | -0.4% | 39,791 | -26.6% | 0.00% | 0.0% |
| Q2 2017 | $695,000 | +149.1% | 54,199 | +152.8% | 0.00% | – |
| Q1 2017 | $279,000 | -12.8% | 21,438 | -33.9% | 0.00% | – |
| Q4 2016 | $320,000 | +1003.4% | 32,434 | +1266.8% | 0.00% | – |
| Q3 2016 | $29,000 | +163.6% | 2,373 | +84.0% | 0.00% | – |
| Q2 2016 | $11,000 | -89.3% | 1,290 | -88.7% | 0.00% | – |
| Q1 2016 | $103,000 | -78.2% | 11,391 | -59.0% | 0.00% | -100.0% |
| Q4 2015 | $473,000 | -13.5% | 27,809 | -34.3% | 0.00% | 0.0% |
| Q3 2015 | $547,000 | +1039.6% | 42,336 | +1845.6% | 0.00% | – |
| Q2 2015 | $48,000 | -18.6% | 2,176 | -47.9% | 0.00% | – |
| Q1 2015 | $59,000 | -65.9% | 4,177 | -78.1% | 0.00% | – |
| Q4 2014 | $173,000 | -23.5% | 19,098 | -23.6% | 0.00% | – |
| Q3 2014 | $226,000 | -33.5% | 24,998 | -33.7% | 0.00% | – |
| Q2 2014 | $340,000 | -26.7% | 37,680 | -2.4% | 0.00% | – |
| Q1 2014 | $464,000 | -37.8% | 38,621 | -27.5% | 0.00% | -100.0% |
| Q4 2013 | $746,000 | +52.2% | 53,275 | +19.8% | 0.00% | – |
| Q3 2013 | $490,000 | -90.9% | 44,477 | -93.4% | 0.00% | -100.0% |
| Q2 2013 | $5,377,000 | – | 676,424 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |